Bioxcel Therapeutics Inc (BTAI)
NASDAQ:BTAI
Want to see BTAI full AI Analyst Report?
BTAI Stock Chart & Stats
$1.15
-$0.09(-19.80%)
At close: 4:00 PM EST
$1.15
-$0.09(-19.80%)
Day’s Range― - ―
52-Week Range$1.01 - $8.08
Previous CloseN/A
Volume1.10M
Average Volume (3M)1.58M
Market Cap
$35.82M
Enterprise Value$119.24M
Total Cash (Recent Filing)$17.18M
Total Debt (Recent Filing)$100.29M
Price to Earnings (P/E)―
Beta2.29
Next Earnings
Aug 11, 2026EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.70
Shares Outstanding30,877,605
10 Day Avg. Volume1,230,633
30 Day Avg. Volume1,584,008
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.20
Price to Sales (P/S)30.42
P/FCF Ratio-0.34
Enterprise Value/Market Cap3.33
Enterprise Value/Revenue175.35
Enterprise Value/Gross Profit630.88
Enterprise Value/Ebitda-2.00
Forecast
1Y Price Target
$7.67Price Target Upside566.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.81
Revenue Forecast (FY)$1.65M
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressGovernment-funded and university-led clinical studies of BXCL501 for acute stress reactions aim to demonstrate symptom reduction and cognitive benefit, which could validate broader therapeutic uses if results are favorable.
Regulatory Label ExpansionFDA acceptance of a supplemental application and a regulatory review for at-home use of IGALMI in agitation associated with bipolar disorder and schizophrenia could enable home-based prescribing and materially expand the product's addressable market.
Safety And Competitive ProfileMid-stage data showing reduced opioid withdrawal symptoms with fewer cardiovascular side effects and no reported sedation suggest a more tolerable alternative to current treatments, supporting differentiation versus standard therapy.
Bears Say
Analyst Sentiment And Valuation ImpactRecent share dilution prompting analyst downgrades has reduced near-term valuation expectations and could weigh on investor sentiment going forward.
Commercial Execution And ReimbursementChallenges in building a commercial infrastructure and securing favorable reimbursement terms could limit product uptake and revenue even with positive clinical data.
Financing And Dilution RiskNeed for additional funding to support commercialization increases the likelihood of shareholder dilution and can pressure near-term valuation.
Bioxcel Therapeutics News
BTAI FAQ
What was Bioxcel Therapeutics Inc’s price range in the past 12 months?
Bioxcel Therapeutics Inc lowest stock price was $1.01 and its highest was $8.08 in the past 12 months.
What is Bioxcel Therapeutics Inc’s market cap?
Bioxcel Therapeutics Inc’s market cap is $35.82M.
When is Bioxcel Therapeutics Inc’s upcoming earnings report date?
Bioxcel Therapeutics Inc’s upcoming earnings report date is Aug 11, 2026 which is in 67 days.
How were Bioxcel Therapeutics Inc’s earnings last quarter?
Bioxcel Therapeutics Inc released its earnings results on May 15, 2026. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.532 by -$0.008.
Is Bioxcel Therapeutics Inc overvalued?
According to Wall Street analysts Bioxcel Therapeutics Inc’s price is currently Undervalued.
Does Bioxcel Therapeutics Inc pay dividends?
Bioxcel Therapeutics Inc does not currently pay dividends.
What is Bioxcel Therapeutics Inc’s EPS estimate?
Bioxcel Therapeutics Inc’s EPS estimate is -0.42.
How many shares outstanding does Bioxcel Therapeutics Inc have?
Bioxcel Therapeutics Inc has 30,877,605 shares outstanding.
What happened to Bioxcel Therapeutics Inc’s price movement after its last earnings report?
Bioxcel Therapeutics Inc reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.532. Following the earnings report the stock price went down -5.785%.
Which hedge fund is a major shareholder of Bioxcel Therapeutics Inc?
Currently, no hedge funds are holding shares in BTAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bioxcel Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.67 (566.67% Upside)
$7.67 (566.67% Upside)
Hedge Fund Trend
Decreased
By 1.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.70%
12-Months-Change
Fundamentals
Return on Equity
75.79%
Trailing 12-Months
Asset Growth
-11.77%
Trailing 12-Months
Company Description
Bioxcel Therapeutics Inc
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
BTAI Stock 12 Month Forecast
Average Price Target
$7.67
▲(566.67% Upside)
Technical Analysis
Ownership Overview
2.78% Insiders
1.64% Mutual Funds
7.20% Other Institutional Investors
87.71% Public Companies and
Individual Investors